Sophie V. Vandebroek - May 6, 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Sophie V. Vandebroek
Stock symbol
IDXX
Transactions as of
May 6, 2025
Transactions value $
$0
Form type
4
Date filed
5/8/2025, 07:01 PM
Previous filing
May 1, 2025
Next filing
May 13, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vandebroek Sophie V. Director ONE IDEXX DRIVE, WESTBROOK /s/ Lily J. Lu, Attorney-in-Fact for Sophie V. Vandebroek 2025-05-08 0001442078

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Restricted Stock Unit Options Exercise $0 -262 -100% $0.00 0 May 6, 2025 Common Stock 262 Direct F1
transaction IDXX Non-Qualified Stock Option (right-to-buy) Award $0 +600 $0.00 600 May 7, 2025 Common Stock 600 $486.61 Direct F2
transaction IDXX Restricted Stock Unit Award $0 +257 $0.00 257 May 7, 2025 Common Stock 257 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier.
F2 Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier.
F3 Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event earlier.